Advances in BABE

In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

  • Application of Nano technology to improve bioavailabilty
  • Innovative strategies
  • Isotope drug studies in man
  • Bioequivalence Criteria
  • Risks in bioequivalence assessment
  • Requirement to determine the active principle
  • SUPAC: scale-up and for post-approval changes
  • Relevance of bioequivalence in approving generic copies of drug products
  • Electronic regulatory submission and review
  • Drug application regulatory compliance
  • New drug quality assessment
  • Highly variable and low permeable drugs
  • Complex generics

Related Conference of Advances in BABE

September 25-26, 2017(10 Plenary Forums- 1 Event)

7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR

Chicago, Illinois, USA
September 25-26, 2017
(10 Plenary Forums - 1Event)

6th International Conference and Exhibition on GMP, GCP & Quality Control

Chicago, Illinois, USA
October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Advances in BABE Conference Speakers

Recommended Sessions

Related Journals

Are you interested in